Pediatric Clinics of North America - CIPERJ

374 RODRIGUEZ & HOOTS
[2] Berntorp E, Astermark J, Bjorkman S, et al. Consensus perspectives on prophylactic therapy
for haemophilia: summary statement. Haemophilia 2003;9(Suppl 1):1–4.
[3] Galiè N, Seeger W, Naeije R, et al. Comparative analysis of clinical trials and evidence-based
treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:81–8.
[4] Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment
to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;
357(6):535–44.
[5] Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should
be started at an early age but can be individualized. Br J Haematol 1999;105(4):1109–13.
[6] Funk M, Schmidt H, Escuriola-Ettingshausen C, et al. Radiological and orthopedic score in
pediatric hemophilic patients with early and late prophylaxis. Ann Hematol 1998;77(4):
171–4.
[7] Kreuz W, Escuriola-Ettingshausen C, Funk M, et al. When should prophylactic treatment in
patients with haemophilia A and B start–The German experience. Haemophilia 1998;4(4):
413–7.
[8] Petrini P, Lindvall N, Egberg N, et al. Prophylaxis with factor concentrates in preventing
hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991;13(3):280–7.
[9] Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic
treatment on long-term outcome in patients with severe hemophilia. Blood 2002;99(7):
2337–41.
[10] Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes
for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group.
J Intern Med 1994;236(4):391–9.
[11] Smith PS, Teutsch SM, Shaffer PA, et al. Episodic versus prophylactic infusions for hemophilia
A: a cost-effectiveness analysis. J Pediatr 1996;129(3):424–31.
[12] Szucs TD, Offner A, Kroner B, et al. Resource utilisation in haemophiliacs treated in
Europe: results from the European Study on Socioeconomic Aspects of Haemophilia
Care. The European Socioeconomic Study Group. Haemophilia 1998;4(4):498–501.
[13] Fischer K, van der Bom JG, Molho P, et al. Prophylactic versus on-demand treatment strategies
for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia
2002;8(6):745–52.
[14] Petrini P. What factors should influence the dosage and interval of prophylactic treatment in
patients with severe haemophilia A and B Haemophilia 2001;7(1):99–102.
[15] van den Berg HM, Fischer K, Mauser-Bunschoten EP, et al. Long-term outcome of individualized
prophylactic treatment of children with severe haemophilia. Br J Haematol 2001;
112(3):561–5.
[16] Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim
results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.
J Thromb Haemost 2006;4(6):1228–36.
[17] Villar A, Jimenez-Yuste V, Quintana M, et al. The use of haemostatic drugs in haemophilia:
desmopressin and antifibrinolytic agents. Haemophilia 2002;8:189–93.
[18] Galves A, Gomez-Ortiz G, Diaz-Ricart M, et al. Desmopressin (DDAVP) enhances platelet
adhesion to the extracellular matrix of cultured human endothelial cells through increased
expression of tissue factor. Thromb Haemost 1997;77:975–80.
[19] Winterbottom N, Kuo JM, Nguyen K, et al. Antigenic responses to bovine thrombin exposure
during surgery: a prospective study of 309 patients. Journal of Applied Research 2002;2:
1–11.
[20] Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that ‘new variant’
CJD is caused by the BSE agent. Nature 1997;389(6650):498–501.
[21] Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative
study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin
in surgical hemostasis. J Am Coll Surg 2007 Aug;205(2):256–65.